Alnylam Pharmaceuticals exceeded earnings per share expectations for Q3 2024, though revenues fell short. The biotech company has suspended further development of a Type 2 diabetes treatment, while Q3 earnings indicate a sharp drop in revenue. It has negotiated a tech services partnership with Cognizant to scale its IT operations. Alnylam's cardiomyopathy drug is progressing with regulatory filing procedures in the EU. The company is ramping up its operations in anticipation of a significant reveal at AHA scientific sessions, expected to showcase latest data from the TTR Franchise and Hypertension Program. Positive results from a pivotal study on a heart drug, which may clear the way for approval, led to Alnylam's shares surging. The establishment of an RNAi-based medicine startup by the company's founding CEO is a noteworthy development. However, Alnylam's heart drug data was considered disappointing by some investors, resulting in a stock slide. There is a positive analyst outlook for Alnylam's stock price, and the company's path to profitability is being closely tracked.
Alnylam Pharmaceuticals News Analytics from Thu, 15 Feb 2024 08:00:00 GMT to Sat, 02 Nov 2024 08:42:19 GMT -
Rating 1
- Innovation 8
- Information 5
- Rumor -2
